Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage...
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement,...
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily,...
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety...
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 ...
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
Virtual presentation scheduled for Thursday, February 26 th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade...
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...